Epilepsy and Seizure Disorders

Epilepsy affects approximately 3.4 million people in the United States, according to the Centers for Disease Control and Prevention (CDC), making it one of the most prevalent chronic neurological conditions treated within the broader field covered at neurologicalauthority.com. This page covers the definition and classification of epilepsy and seizure disorders, the underlying neural mechanisms that produce seizure activity, the clinical scenarios in which these disorders present, and the diagnostic and treatment boundaries that guide clinical decision-making. Understanding the distinctions between seizure types, syndromes, and epilepsy classifications directly affects how patients are evaluated, monitored, and managed under established medical and regulatory frameworks described in the regulatory context for neurological conditions.

Definition and Scope

Epilepsy is defined by the International League Against Epilepsy (ILAE) as a disease of the brain characterized by an enduring predisposition to generate epileptic seizures, with the associated neurobiological, cognitive, psychological, and social consequences (ILAE 2014 Operational Definition). A single unprovoked seizure does not meet the ILAE diagnostic threshold for epilepsy; the clinical definition requires either two unprovoked seizures occurring more than 24 hours apart, or one unprovoked seizure with a probability of further seizures exceeding 60% over the next 10 years.

A seizure, by contrast, is a discrete event — a transient occurrence of signs or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. Seizures can be provoked (caused by a reversible insult such as hypoglycemia, fever in children, alcohol withdrawal, or acute head injury) or unprovoked. Only unprovoked seizures anchor the epilepsy diagnosis.

The ILAE classification framework, last substantially revised in 2017, organizes seizures along three primary axes: seizure type, epilepsy type, and epilepsy syndrome. The CDC estimates epilepsy carries an annual economic burden exceeding $15.5 billion in the United States, encompassing direct medical costs and lost productivity (CDC Epilepsy Fast Facts).

How It Works

Seizure generation arises from an imbalance between excitatory and inhibitory neurotransmission at the neuronal level. Glutamate is the primary excitatory neurotransmitter, while gamma-aminobutyric acid (GABA) provides the principal inhibitory signal. When excitatory activity surpasses inhibitory thresholds across a sufficient population of neurons, synchronized electrical discharges propagate through cortical networks, producing the clinical and electrographic features of a seizure.

The specific propagation pattern determines seizure type. The 2017 ILAE Operational Classification identifies two primary onset categories:

Focal onset seizures — originate in networks limited to one cerebral hemisphere. These are further divided into:
Focal aware (formerly simple partial): consciousness is preserved
Focal impaired awareness (formerly complex partial): consciousness is altered
Focal to bilateral tonic-clonic: spreads from a focal region to involve both hemispheres
Generalized onset seizures — originate in and rapidly engage bilaterally distributed networks from the outset. Subtypes include:
Tonic-clonic (formerly grand mal)
Absence (formerly petit mal): brief lapses in awareness, typically 10–30 seconds
Myoclonic: brief, shock-like muscle jerks
Atonic: sudden loss of muscle tone
Tonic: sustained muscle stiffening
Clonic: rhythmic, repetitive jerking
Unknown onset — used when onset cannot be determined from available data

An electroencephalogram (EEG) is the primary electrophysiological tool for characterizing seizure onset zones and epileptiform discharges. Structural causes are evaluated through MRI of the brain and spine.

Genetic, structural, metabolic, immune, infectious, and unknown etiologies each constitute a distinct ILAE etiological category, and the specific etiology shapes both prognosis and treatment selection (ILAE Classification of the Epilepsies 2017).

Common Scenarios

Epilepsy presents across all age groups, but onset patterns differ significantly by age:

Childhood absence epilepsy typically begins between ages 4 and 10, features absence seizures occurring up to hundreds of times per day, and carries a favorable prognosis for remission in adolescence.
Juvenile myoclonic epilepsy (JME) begins in adolescence, is characterized by myoclonic jerks on awakening, and generally requires lifelong antiseizure medication because relapse rates following medication withdrawal exceed 80% (ILAE clinical guidelines).
Temporal lobe epilepsy (TLE) is the most common focal epilepsy in adults; hippocampal sclerosis is the single most frequently identified structural cause on MRI.
Post-stroke epilepsy affects approximately 10–15% of stroke survivors, as documented in epidemiological reviews cited by the American Epilepsy Society (AES).
Febrile seizures affect 2–5% of children between 6 months and 5 years of age (National Institute of Neurological Disorders and Stroke, NINDS) and are provoked events; the majority do not represent epilepsy.

Status epilepticus — a seizure lasting more than 5 minutes or two seizures without full recovery of consciousness between them — is a neurological emergency with mortality rates ranging from 10% to 30% depending on etiology and duration (Neurocritical Care Society Guidelines). Guidance on immediate response steps is detailed at seizures: what to do.

Long-term daily life management, including driving restrictions, employment considerations, and seizure first aid protocols, is addressed at managing epilepsy and daily life.

Decision Boundaries

The boundary between epilepsy and non-epileptic events represents one of the most clinically consequential distinctions in neurology. Psychogenic non-epileptic seizures (PNES) account for approximately 20–30% of patients referred to epilepsy monitoring units, according to the Epilepsy Foundation. PNES require video-EEG monitoring — capturing a clinical event with simultaneous EEG — to confirm the absence of ictal correlate. Misclassification carries serious risks, including inappropriate antiseizure medication exposure.

Key diagnostic and management boundaries include:

Single seizure vs. epilepsy — a single unprovoked seizure triggers risk stratification, not automatic epilepsy diagnosis; EEG abnormality, structural lesion on MRI, or nocturnal onset each significantly elevate recurrence probability
Provoked vs. unprovoked — provoked seizures (e.g., hyponatremia, alcohol withdrawal) require treatment of the underlying cause rather than long-term antiseizure medication
Drug-resistant epilepsy — defined by the ILAE as failure of adequate trials of 2 tolerated and appropriately chosen antiseizure medication schedules; at that threshold, evaluation for surgical treatment for epilepsy is indicated
Epilepsy syndrome resolution — some syndromes, such as childhood absence epilepsy and benign epilepsy with centrotemporal spikes (BECTS), carry recognized age-dependent remission; others, such as Dravet syndrome and Lennox-Gastaut syndrome, are lifelong and pharmacoresistant
Teratogenicity and reproductive counseling — the FDA classifies valproate as contraindicated in pregnancy for certain indications due to fetal risk; prescribers follow FDA Risk Evaluation and Mitigation Strategy (REMS) requirements (FDA Valproate REMS)

Subspecialty evaluation through an epilepsy fellowship-trained neurologist is standard of care for drug-resistant cases and complex pediatric epilepsy syndromes. Neuropsychological evaluation — detailed at neuropsychological testing — is an integrated component of surgical candidacy workup, as temporal lobe resection carries measurable risk to verbal memory when performed on the language-dominant hemisphere.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)